Island Pharmaceuticals Ltd (ILA) fair value: what the stock is really worth
As of Oct 6, 2026: fair value of Island Pharmaceuticals Ltd A$0.03, price A$0.37, upside -90.7%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 5, 2026.
How to read this chart
60‑month range A$0.0530 – A$0.5700 · fair‑value band A$0.0255 – A$0.0425 · the A$0.3650 price screens above the A$0.0340 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 5, 2026.
Follow Island Pharmaceuticals in your weekly email
Every Wednesday you see whether Island Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases.
Show more
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Stock analysis
Island Pharmaceuticals Ltd (ILA) currently trades at A$0.3650, while our model-based Fair Value estimate is A$0.0340, 90.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: A$0.0255 (bear) to A$0.0425 (bull), the price of A$0.3650 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Island Pharmaceuticals Ltd reported revenue of A$283K in FY2025 versus A$0 in FY2021. Reported net income was −A$9.8M in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 36% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −91%, ILA screens richer than that median.
Fair Value models
Bear A$0.0255Fair Value A$0.0340Bull A$0.0425
Price A$0.3650 · Upside -90.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+137.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+194.5%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26,282.2% (2022) → −3,756.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Island Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−91.1% · Bottom 25%
Profitability
Return on assets−60.1% · Bottom 25%
Growth and dividend
Revenue growth996.0% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B5.80× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Island Pharmaceuticals Ltd (ILA) overvalued or undervalued?
As of Oct 5, 2026, our model estimates a fair value of A$0.0340 versus a price of A$0.3650, about −91% upside (overvalued).
What is the fair value of ILA?
Our model-based fair value for Island Pharmaceuticals Ltd is A$0.0340 (as of Oct 5, 2026), built from audited fundamentals. The current price: A$0.3650.
What is the quality score of ILA?
Island Pharmaceuticals Ltd has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Island Pharmaceuticals Ltd (ILA)?
Our model-based price target is the fair value of A$0.0340 (as of Oct 5, 2026) from 1 valuation models. Cautious scenario A$0.0255, optimistic scenario A$0.0425. It is a calculation from audited fundamentals, not an analyst target.
What is the Island Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at A$0.0340, about −91% upside versus a price of A$0.3650 (overvalued). Cautious scenario A$0.0255, optimistic scenario A$0.0425. The calculation is refreshed regularly with new filings.
What is the revenue of Island Pharmaceuticals Ltd (ILA)?
Island Pharmaceuticals Ltd reported trailing-twelve-month revenue of about A$283K (latest available figure, as of Oct 5, 2026).
What is the intrinsic value of Island Pharmaceuticals Ltd (ILA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Island Pharmaceuticals Ltd it is A$0.0340 per share (as of Oct 5, 2026), against a price of A$0.3650. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Island Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Oct 5, 2026, ILA trades above its calculated fair value: price A$0.3650, fair value A$0.0340, a gap of about −91% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ILA?
No. The price is what the market pays today (A$0.3650); the fair value is what the company's own numbers justify (A$0.0340). For Island Pharmaceuticals Ltd the two are A$0.3310 per share apart. That gap is exactly why we show both numbers side by side.
How much is Island Pharmaceuticals Ltd worth?
The market values Island Pharmaceuticals Ltd at about A$108M (market capitalisation, as of Oct 5, 2026). Per share that is A$0.3650; our models calculate a fair value of A$0.0340 per share.
What do the bullish and bearish scenarios say about ILA?
Our models span a range for Island Pharmaceuticals Ltd: cautious scenario A$0.0255, base A$0.0340, optimistic A$0.0425 per share (as of Oct 5, 2026, price A$0.3650). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Island Pharmaceuticals Ltd (ILA)?
Balance-sheet figures for Island Pharmaceuticals Ltd (as of Oct 5, 2026): return on equity −95.5%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is ILA from its 52-week high?
Island Pharmaceuticals Ltd trades at A$0.3650, about 36% below its 52-week high of A$0.5700 and 16% above the low of A$0.3150 (as of Oct 6, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0340 is for.
Which stocks are comparable to Island Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Island Pharmaceuticals Ltd stock attractive at the current price?
The data as of Oct 5, 2026: price A$0.3650, calculated fair value A$0.0340 (−91%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ILA calculated?
We run Island Pharmaceuticals Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0340, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Island Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Island Pharmaceuticals Ltd (ILA)?
The closing price on Oct 6, 2026 was A$0.3650. Our model-based fair value is A$0.0340, about −91% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Island Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (A$0.0425). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Island Pharmaceuticals Ltd
How large is the market capitalisation of Island Pharmaceuticals Ltd (ILA)?
The market capitalisation of Island Pharmaceuticals Ltd is A$108M (≈ $75.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Island Pharmaceuticals Ltd (ILA)?
Earnings per share at Island Pharmaceuticals Ltd are A$−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Island Pharmaceuticals Ltd (ILA)?
The return on equity (ROE) of Island Pharmaceuticals Ltd is −95.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Island Pharmaceuticals Ltd (ILA)?
On an EBIT basis the return on assets of Island Pharmaceuticals Ltd is −109% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Island Pharmaceuticals Ltd (ILA)?
The operating margin of Island Pharmaceuticals Ltd is −2,240% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Island Pharmaceuticals Ltd (ILA)?
Revenue at Island Pharmaceuticals Ltd is growing +996% versus a year earlier (3y avg +195%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Island Pharmaceuticals Ltd (ILA) generate?
The free cash flow of Island Pharmaceuticals Ltd is −A$4.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Island Pharmaceuticals Ltd (ILA) hold?
Island Pharmaceuticals Ltd holds more cash than debt, A$12.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Island Pharmaceuticals Ltd in the live analysis
One click puts Island Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
